Filtered By:
Nutrition: Vitamin K
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 1818 results found since Jan 2013.
Selecting the right anticoagulant for stroke prevention in atrial fibrillation
CONCLUSIONS: Non-valvular AF patients on apixaban had lower rates of thromboembolic events than the patients on acenocumarol. This article will serve as a reminder of the positive health and financial outcomes of apixaban use, especially to those healthcare systems that are still oblivious to the decrease in economic burden and gain in quality-adjusted life years (QALY) by the long-term use of NOACS/ DOACS instead of the AVK anticoagulants.PMID:34286492 | DOI:10.26355/eurrev_202107_26241
Source: European Review for Medical and Pharmacological Sciences - July 21, 2021 Category: Drugs & Pharmacology Authors: N R Kundnani C I Rosca A Sharma A Tudor M S Rosca D D Nisulescu H S Branea V Mocanu D C Crisan D R Buzas S Morariu D F Lighezan Source Type: research
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study
CONCLUSIONS: Although the non-randomized nature of the study is prone to bias, anticoagulation with VKA was not associated with decreased thromboembolic risk, but associated with increased risk of major bleeding and may be net-harmful to patients with AF on HD.PMID:34418291 | DOI:10.1111/jth.15508
Source: Thrombosis and Haemostasis - August 21, 2021 Category: Hematology Authors: Oliver K önigsbrügge Hannah Meisel Aljoscha Beyer Sabine Schmaldienst Renate Klauser-Braun Matthias Lorenz Martin Auinger Josef Kletzmayr Manfred Hecking Wolfgang C Winkelmayer Irene Lang Ingrid Pabinger Marcus S äemann Cihan Ay Source Type: research
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
ConclusionBased on current evidence, for stroke prevention and treatment in patients with AF, the most safe DOAC is edoxaban in terms of fatal bleeding; dabigatran in terms of major bleeding and intracranial hemorrhage and apixaban in terms of gastrointestinal bleeding. However, given the nature of indirect comparisons, more high-quality evidence from head-to-head comparisons is still needed to confirm them.
Source: Cardiovascular Drugs and Therapy - August 26, 2021 Category: Cardiology Source Type: research
Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation & lt;48 h duration: results of an EHRA survey
AbstractData supporting the safety of cardioversion (CV) of atrial fibrillation (AF) without anticoagulation in patients with AF duration<48 h are scarce. Observational studies suggest that the risk of stroke in these patients is very low when the definite duration of the AF episode is of<48 h and the clinical risk profile as estimated through the CHA2DS2VASc score is low (a score of 0 for men and 1 for women). As the recent 2020 European Society of Cardiology (ESC) guidelines indication for this clinical scenario is based mainly on consensus, we sent out a survey to assess the current clinical practice on anti...
Source: Europace - May 15, 2021 Category: Cardiology Source Type: research
Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants
We report a case of an ischemic stroke after a successful catheter ablation of atrial fibrillation (AF) and continuous oral anticoagulation therapy with direct oral anticoagulants (DOACs), which was the trigger for diagnosing antiphospholipid syndrome (APS). A 68-year-old woman underwent catheter ablation of persistent AF and continued oral anticoagulation with edoxaban at a dose of 30 mg once daily after the ablation procedure. An asymptomatic intracerebral hemorrhage was detected by brain computed tomography and magnetic resonance imaging one month post-ablation. Oral anticoagulation with dabigatran at 110 mg twice daily...
Source: International Heart Journal - January 31, 2022 Category: Cardiology Authors: Yumiko Haraguchi Kohki Nakamura Mitsuho Inoue Takehito Sasaki Kentaro Minami Shingo Yoshimura Shigeto Naito Source Type: research
